DSIP 5mg

Description

DSIP (5mg) is a high-purity, synthetic Delta Sleep-Inducing Peptide supplied as a lyophilized (freeze-dried) powder in a single sterile vial. This 5mg vial is intended exclusively for laboratory and scientific research purposes, including in vitro experiments, animal models, neurophysiological studies, or biochemical assays. DSIP is not approved for human consumption, therapeutic use, medical treatment, dietary supplementation, or veterinary applications by any regulatory agency (e.g., FDA, EMA). All handling must be performed by qualified researchers following strict laboratory and biosafety protocols.

Key Specifications

• Chemical Name: Delta Sleep-Inducing Peptide
• Molecular Formula: C₃₅H₄₈N₁₀O₁₅
• Molecular Weight: 848.81–848.83 g/mol
• Amino Acid Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE)
• CAS Number: 62568-57-4
• Synonyms: Emideltide, Delta Sleep Peptide, DSIP nonapeptide
• Purity: ≥98–99% (verified by HPLC; third-party Certificate of Analysis recommended)
• Appearance: White to off-white lyophilized powder
• Form: Single 5mg vial (requires reconstitution with bacteriostatic water, sterile water, or appropriate buffer for research use)
• Storage: Lyophilized — store at -20°C or colder, protected from light and moisture for long-term stability. After reconstitution — refrigerate at 2–8°C and use promptly (stability typically days to weeks depending on buffer and conditions). Avoid repeated freeze-thaw cycles.

Research Background and Mechanism

DSIP was first isolated in 1977 from the cerebral venous blood of rabbits during sleep induction experiments. It is a nonapeptide that has been studied for over four decades, primarily in preclinical (animal) and limited human research settings during the 1980s–1990s. DSIP is considered an endogenous neuromodulator with a broad range of proposed effects on sleep architecture, stress response, and neuroendocrine regulation.

Key mechanisms explored in research models include:

• Promotion of slow-wave sleep (delta sleep) and normalization of disturbed sleep patterns
• Modulation of the hypothalamic-pituitary-adrenal (HPA) axis, reducing stress-induced ACTH and cortisol release
• Influence on opioid, GABAergic, and serotonergic systems
• Potential antioxidant and cytoprotective effects in models of oxidative stress
• Regulation of circadian rhythms and thermoregulation
• Possible roles in pain modulation and withdrawal symptom attenuation in certain models

Animal studies (rats, rabbits) have shown DSIP to increase delta-wave EEG activity, improve sleep efficiency after stress or disruption, and exhibit stress-protective (anti-ulcer, anti-hypoxic) properties without strong sedative or hypnotic effects typical of benzodiazepines.

Potential Research Applications

In controlled laboratory settings, DSIP is investigated for:

• Mechanisms of sleep regulation and delta-wave generation
• Stress physiology and HPA axis modulation
• Neuroendocrine interactions under chronic stress or sleep deprivation
• Potential neuroprotective or cytoprotective effects in models of ischemia, oxidative damage, or metabolic stress
• Pain and nociception pathways
• Circadian rhythm disorders and chronobiology

Notably, DSIP shows a unique profile: it does not induce general sedation or motor impairment in many models, distinguishing it from classical hypnotics.

Important Notes

DSIP remains unapproved for any human or clinical use. Early clinical trials in the 1980s–1990s produced mixed results on sleep efficacy, and development did not progress to modern regulatory approval. All products labeled DSIP are sold strictly for research use only — not for diagnostic, therapeutic, personal consumption, or performance enhancement purposes. Researchers must use sterile reconstitution techniques (gentle swirling, avoid vigorous agitation), proper storage, and biosafety measures. Always verify purity and identity via independent lab analysis (COA) and comply with institutional guidelines.